Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Miniature By Design: Tarveda's Small Conjugates Could Be Better Fit For HSP90

Executive Summary

Biotech's internally derived Pentarins offer the targeting advantages of antibody-drug conjugates in cancer, but with better affinity, pharmacokinetics and deeper tumor penetration.

You may also be interested in...



Refocusing Tarveda On Tumor-Targeted Mini-Drug Conjugates

Emerging Company Profile: Tarveda Therapeutics has refocused during the past 18 months on its Pentarin technology. The company has raised $91.8m to date, including a recent $30m Series D round, which it will use to produce human data that could make it attractive to investors or pharma partners.

Roche's Kadcyla set for EU launch, perhaps in Germany

Roche is preparing to launch HER2 positive breast cancer antibody-drug conjugate Kadcyla (trastuzumab emtansine) in Europe following approval from the European Commission.

Synta’s Ganetespib Could Break The Hsp90i Curse

If ganetespib succeeds in Phase III, it could become the first new treatment for advanced lung adenocarcinoma in a decade, but the heat shock protein class has yet to produce a winner.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

GB150348

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel